Evidence map›Paper›PMID 24704827›Full record

ArticleOncogene2015

IGF2BP1 controls cell death and drug resistance in rhabdomyosarcomas by regulating translation of cIAP1.

M D Faye, S T Beug, T E Graber, N Earl, X Xiang, B Wild, S Langlois, J Michaud, K N Cowan, R G Korneluk and 1 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 59 citations in OpenAlex.

  1. Functional Characterization ofAnimals : an open access journal from MDPI · 2026
    Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. IGF2BPs as novel mGenes & diseases · 2024
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Role of m6A writers, erasers and readers in cancer.Experimental hematology & oncology · 2022
    Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

M D Faye1] Apoptosis Research Centre, Children's Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada [2] Department of Biochemistry, Microbiology and Immunology, University of Ottawa, ON, Ottawa, Canada.
S T BeugApoptosis Research Centre, Children's Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada.
T E GraberApoptosis Research Centre, Children's Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada.
N EarlApoptosis Research Centre, Children's Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada.
X Xiang1] Apoptosis Research Centre, Children's Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada [2] Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON, Canada.
B Wild1] Apoptosis Research Centre, Children's Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada [2] Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON, Canada.
S Langlois1] Apoptosis Research Centre, Children's Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada [2] Department of Surgery, University of Ottawa, Ottawa, ON, Canada.
J MichaudDepartment of Pathology and Laboratory Medicine, University of Ottawa, The Ottawa Hospital and Children's Hospital of Eastern Ontario, Ottawa, ON, Canada.
K N Cowan1] Apoptosis Research Centre, Children's Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada [2] Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON, Canada [3] Department of Surgery, University of Ottawa, Ottawa, ON, Canada.
R G Korneluk1] Apoptosis Research Centre, Children's Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada [2] Department of Biochemistry, Microbiology and Immunology, University of Ottawa, ON, Ottawa, Canada [3] Department of Pediatrics, University of Ottawa, Ottawa, ON, Canada.
M Holcik1] Apoptosis Research Centre, Children's Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada [2] Department of Biochemistry, Microbiology and Immunology, University of Ottawa, ON, Ottawa, Canada [3] Department of Pediatrics, University of Ottawa, Ottawa, ON, Canada.
Children's Hospital of Eastern Ontario · CAUniversity of Ottawa · CA

Funding

Canadian Institutes of Health Research FRN 74740
6 · The paper itself

Abstract

Rhabdomyosarcoma (RMS), a neoplasm characterised by undifferentiated myoblasts, is the most common soft tissue tumour of childhood. Although aggressive treatment of RMS could provide long-term benefit, resistance to current therapies is an ongoing problem. We report here that insulin-like growth factor 2-binding protein 1 (IGF2BP1), an oncofetal protein, is expressed in RMS patient-derived cell lines and in primary tumours where it drives translation of the cellular inhibitor of apoptosis 1 (cIAP1), a key regulator of the nuclear factor-κB signalling pathway and of caspase-8-mediated cell death. We demonstrate that reducing the levels of cIAP1 in RMS, either by IGF2BP1 knockdown or by IAP antagonists, sensitises these cells to tumour necrosis factor-α-mediated cell death. Finally, we show that targeting cIAP1 by IAP antagonists delays RMS tumour growth and improve survival in mice. Our results identify IGF2BP1 as a critical translational regulator of cIAP1-mediated apoptotic resistance in RMS and advocate for the combined use of IAP antagonists and tumour necrosis factor-α as a therapeutic approach for this type of cancer.

Indexed as

Drug Resistance, NeoplasmAlkynesAnimalsApoptosisCell Line, TumorDipeptidesFemaleGene Expression Regulation, NeoplasticHEK293 CellsHumansInhibitor of Apoptosis ProteinsMiceMice, NudeNeoplasm TransplantationProtein BiosynthesisRhabdomyosarcomaAEG 40730AlkynesBIRC2 protein, humanBirc2 protein, mouseCRD-BP protein, mouseDipeptidesIGF2BP1 protein, humanInhibitor of Apoptosis ProteinsLCL161RNA-Binding ProteinsThiazolesTumor Necrosis Factor-alphaUbiquitin-Protein Ligases

Identifiers

PMID24704827
OpenAlexW2070419157

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.